|
1 Indications And Usage Risedronate Sodium Is A Bisphosphonate In A Delayed-Release Formulation And Is Indicated For Treatment Of Postmenopausal Osteoporosis ( 1.1 ) Limitations Of Use Optimal Duration Of Use Has Not Been Determined. For Patients At Low-Risk For Fracture, Consider Drug Discontinuation After 3 To 5 Years Of Use ( 1.2 ) 1.1 Postmenopausal Osteoporosis Risedronate Sodium Is Indicated For The Treatment Of Osteoporosis In Postmenopausal Women. In Postmenopausal Women, Risedronate Sodium Has Been Shown To Reduce The Incidence Of Vertebral Fractures And A Composite Endpoint Of Nonvertebral Osteoporosis-Related Fractures [ See Clinical Studies (14.1) ]. 1.2 Important Limitations Of Use The Optimal Duration Of Use Has Not Been Determined. The Safety And Effectiveness Of Risedronate Sodium For The Treatment Of Osteoporosis Are Based On Clinical Data Of One Year Duration. All Patients On Bisphosphonate Therapy Should Have The Need For Continued Therapy Re-Evaluated On A Periodic Basis. Patients At Low-Risk For Fracture Should Be Considered For Drug Discontinuation After 3 To 5 Years Of Use. Patients Who Discontinue Therapy Should Have Their Risk For Fracture Re-Evaluated Periodically.
|